

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H2 2020

<https://marketpublishers.com/r/V4F719D9509EN.html>

Date: October 2020

Pages: 94

Price: US\$ 2,500.00 (Single User License)

ID: V4F719D9509EN

Abstracts

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H2 2020, provides an overview of the Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline landscape.

Vaso-occlusive crisis associated with sickle cell disease is a painful episode that occurs in people who have sickle cell anemia. Symptoms include fever, pain, fatigue, abdominal pain and swelling, headaches, shortness of breath, dehydration and infection. Treatment includes NSAIDs, acetaminophen, blood transfusion and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease and features dormant and

discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 3, 1 and 4 respectively.

Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular).

The pipeline guide reviews pipeline therapeutics for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Vaso-Occlusive Crisis Associated With Sickle Cell

Disease (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Overview

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Therapeutics Development Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Therapeutics Assessment Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Companies Involved in Therapeutics Development

Asklepion Pharmaceuticals LLC

AstraZeneca Plc

Bristol-Myers Squibb Co

Cyclerion Therapeutics Inc

Global Blood Therapeutics Inc

GlycoMimetics Inc

Hartis Pharma SA

KM Biologics Co Ltd

NicOx SA

Novartis AG

Prolong Pharmaceuticals LLC

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Drug Profiles

apadamtase alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

apixaban - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

crizanlizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HRT-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

inclacumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

L-Citrulline - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naproxcinod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

olinciguat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rivipansel sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sanguinate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ticagrelor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Dormant Projects

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Discontinued Products

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Product Development

Milestones

Featured News & Press Releases

Oct 05, 2020: FDA grants GlycoMimetics Rare Pediatric Disease Designation for Rivipansel for treatment of sickle cell disease

Jun 12, 2020: New efficacy and biomarker data from Rivipansel phase 3 RESET trial to be presented at Sickle Cell meeting

Dec 20, 2019: Novartis wins Medicaid approval for new sickle cell drug in key US states

Nov 18, 2019: FDA approves Novartis' Adakveo for sickle cell disease patients

Aug 05, 2019: Pfizer's RESET trial of rivipansel fails to meet endpoints

Jul 16, 2019: FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)

May 06, 2019: GlycoMimetics announces enrollment completed for phase 3 clinical trial evaluating Rivipansel in Sickle Cell Disease

Jan 09, 2018: Prolong Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference

Dec 13, 2017: Prolong Pharma Announces Completion of Enrollment in Phase II Study of SANGUINATE in the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis in an Ambulatory Setting

Nov 08, 2017: Prolong Pharmaceuticals to Present New Research on SANGUINATE, an Investigational Treatment Under Evaluation for Vaso-Occlusive Crisis in Patients with Sickle Cell Disease, at ASH Annual Meeting

Feb 01, 2017: A multiple drug approach to preventing sickle cell crisis

Oct 29, 2015: GlycoMimetics Announces Initiation of First Clinical Trial Evaluating Subcutaneous Administration of Rivipansel

Oct 29, 2015: Halozyne Announces First Clinical Dosing Of Pfizer's Rivipansel Using Enhance Technology

Jun 23, 2015: GlycoMimetics to Receive \$20 Million Payment from Pfizer Following Initiation of Phase 3 Trial with Rivipansel

Apr 07, 2015: GlycoMimetics Provides Update on Pfizer's Plans to Initiate Phase 3 Trial with Rivipansel in Mid-2015

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease, H2 2020

Number of Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Asklepiion Pharmaceuticals LLC, H2 2020

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by AstraZeneca Plc, H2 2020

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Bristol-Myers Squibb Co, H2 2020

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Cycleron Therapeutics Inc, H2 2020

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Global Blood Therapeutics Inc, H2 2020

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by GlycoMimetics Inc, H2 2020

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Hartis Pharma SA, H2 2020

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by KM Biologics Co Ltd, H2 2020

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by NicOx SA, H2 2020

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Novartis AG, H2 2020

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Prolong Pharmaceuticals LLC, H2 2020

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Dormant Projects, H2 2020

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

I would like to order

Product name: Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/V4F719D9509EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V4F719D9509EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970